Navigation Links
Enzyme may drive breast cancer growth
Date:5/18/2011

A recently discovered enzyme drives the production of a potent form of estrogen in human breast cancer tissue, researchers from the University of Illinois at Chicago College of Medicine have found.

The extra-strength estrogen, called estradiol, then drives the production of even more enzyme, in what may be a lethal feed-forward mechanism. Estradiol has been implicated in exacerbating tumor growth in breast cancer.

The research is published in the May issue of the journal Molecular Endocrinology.

Scientists had observed the increased production of an unknown protein in ovarian tissue in response to estrogen. UIC researchers under the direction of Geula Gibori, UIC professor of physiology and biophysics, then purified the protein and cloned its gene. Several laboratories established that it is an enzyme that converts a weak estrogen, estrone, to the much more potent estradiol.

The UIC researchers then examined the production of the enzyme in a line of breast cancer cells known to respond to estrogen levels.

"Estradiol up-regulates the very enzyme that produces estradiol, creating a positive cycle where this potent form of estrogen is being produced over and over again, sustaining its own production," said Aurora Shehu, UIC postdoctoral research associate in physiology and biophysics and first author of the study.

In human breast tissue, the researchers found a "dramatic" up-regulation in the cancerous cells but not in the surrounding benign tissue, said Gibori, who is principal investigator on the study. The surrounding tissue, however, is a rich source of the estrone that the enzyme needs to produce more estradiol, she said.

The researchers were able to show how estradiol turns on the gene that produces the enzyme, and that this activation also required at least one other known regulatory factor.

They found that tamoxifen, a drug widely used to inhibit breast cancer growth, prevents estradiol's stimulation of the enzyme and thus may shut down local production of estradiol in breast cancer cells.

"Breast cancer tumors with this enzyme are likely to be a much more aggressive and potentially deadly type of cancer," Gibori said. "Identifying this enzyme and how its expression is turned on gives medical researchers potential targets for disrupting the lethal production of estradiol in breast cancers."

The enzyme is a promising therapeutic target because blocking it may halt production only of the dangerous estradiol, which would reduce the side effects seen with other drugs that inhibit production of many estrogen-related compounds, Gibori said.


'/>"/>

Contact: Jeanne Galatzer-Levy
jgala@uic.edu
312-996-1583
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target
2. The TET1 enzyme steers us through fetal development and fights cancer
3. Investigators discover enzyme essential for healthy lung development
4. Newly discovered role for enzyme in neurodegenerative diseases
5. Enzyme helps prepare lung tissue for metastatic development
6. Heart Enzymes May Predict Outcome After Bypass Surgery
7. Breathing easy: LSU biochemists offer first 3-D model of asthma-causing inflammation enzyme
8. Princess Margaret Hospital researchers identify a key enzyme that affects radiation response
9. Chaperone enzyme provides new target for cancer treatments
10. Virus might fight brain tumors better if armed with bacterial enzyme, study shows
11. Enzyme inhibition or removal may prevent or treat ischemic retinopathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 29, 2016 , ... Reltok Nasal Products proudly announces that Boston Medical Products, ... nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product ... a newly patented safety device secured by nasal surgeons onto the floor of the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... media enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, ... as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... and hospice software, outsourced billing and coding services, and Deyta Analytics, recently announced ... hospices providing the highest level of quality as measured from the caregiver’s point ...
(Date:4/29/2016)... ... April 29, 2016 , ... Pro3rd Grunge is a ... Film Studios’ lower thirds to introduce people, characters, and locations without having to set ... lines, accents, textures and many more design components. Simply select a preset and drag ...
(Date:4/28/2016)... ... 2016 , ... Monthly subscription boxes are all the rage, and "My Subscription ... the ZEN BOX , the aromatherapy subscription box. , ZEN BOX delivers three new ... frankincense) and one Zen Blend (like immune boost, sublime sleep or de-stress blends) ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 Dr. Vivek Ahuja , ... Ste phen Schmidt ... provider of cloud-based software solutions for life sciences, today announced key ... a wealth of insight to a growing business.  This will bolster ... George Phillips joined ArisGlobal in the position of Vice ...
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... TURIN, Italy , April 27, 2016 ... MR-guided linear accelerator (MR-linac) platform will be the focal ... annual meeting of the European Society for Radiotherapy & ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and ... a physician to clearly see the patient,s anatomy in ...
Breaking Medicine Technology: